Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

吉非替尼 二甲双胍 医学 内科学 安慰剂 双盲 肿瘤科 表皮生长因子受体 随机对照试验 癌症 胰岛素 病理 替代医学
作者
Li Li,Liyan Jiang,Yubo Wang,Yizhuo Zhao,Xiaoju Zhang,Guoming Wu,Xiangdong Zhou,Jianguo Sun,Jun Bai,Biyong Ren,Kun Tian,Zhixiang Xu,Hualiang Xiao,Qi Zhou,Rui Han,Hengyi Chen,Haidong Wang,Zhenzhou Yang,Chan Gao,Shangli Cai
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:25 (23): 6967-6975 被引量:76
标识
DOI:10.1158/1078-0432.ccr-19-0437
摘要

PURPOSE: Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non-small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs). We therefore examined its effects in combination with gefitinib in patients without diabetes harboring EGFR mutations (EGFRm). PATIENTS AND METHODS: A total of 224 patients without diabetes with treatment-naïve stage IIIB-IV EGFRm NSCLC were randomly assigned in a 1:1 ratio to receive gefitinib plus either metformin or placebo. The primary endpoint was progression-free survival (PFS) rate at 1 year and secondary endpoints included overall survival (OS), PFS, objective response rate (ORR), and safety. Serum levels of IL6 were also examined in an exploratory analysis. RESULTS: = 0.6268). Median PFS (10.3 months vs. 11.4 months) and median OS (22.0 months vs. 27.5 months) were numerically lower in the metformin group, while ORRs were similar between the two arms (66% vs. 66.7%). No significant treatment group differences were detected across all subgroups with respect to PFS, including those with elevated levels of IL6. Metformin combined with gefitinib resulted in a remarkably higher incidence of diarrhea compared with the control arm (78.38% vs. 43.24%). CONCLUSIONS: Our study showed that addition of metformin resulted in nonsignificantly worse outcomes and increased toxicity and hence does not support its concurrent use with first-line EGFR-TKI therapy in patients without diabetes with EGFRm NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qq完成签到,获得积分10
刚刚
1秒前
1秒前
SciGPT的应助被丹亦采纳,获得10
2秒前
3秒前
yaoyaoy完成签到,获得积分10
4秒前
夕禾完成签到,获得积分10
4秒前
布丁奶绿lv完成签到,获得积分10
4秒前
green发布了新的文献求助10
5秒前
5秒前
和谐秋荷完成签到,获得积分10
5秒前
6秒前
小安发布了新的文献求助10
6秒前
范范范完成签到 ,获得积分10
6秒前
焦哈哈发布了新的文献求助10
6秒前
6秒前
深情安青的应助被乐观冥幽采纳,获得10
6秒前
6秒前
7秒前
7秒前
7秒前
7秒前
7秒前
窦天蓝完成签到,获得积分10
7秒前
7秒前
完美世界的应助被XH采纳,获得10
7秒前
7秒前
7秒前
7秒前
8秒前
8秒前
8秒前
lan2720完成签到 ,获得积分10
8秒前
9秒前
9秒前
白色噪音完成签到,获得积分20
10秒前
11秒前
11秒前
Tuniverse_发布了新的文献求助10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181892
求助须知:如何正确求助?哪些是违规求助? 9571628
关于积分的说明 21818984
捐赠科研通 7778258
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557720
邀请新用户注册赠送积分活动 2479621